Immunotherapy of advanced prostate cancer: a phase I/II trial using Mycobacterium vaccae (SRL172)
Open Access
- 1 October 1998
- journal article
- clinical trial
- Published by Wiley in British Journal of Urology
- Vol. 82 (4) , 568-573
- https://doi.org/10.1046/j.1464-410x.1998.00803.x
Abstract
Objective To assess whether a new heat‐killed Mycobacterium vaccae preparation (SRL172), which enhances cell‐mediated immunity and has been proposed for use as an immunotherapeutic agent against ca...Keywords
This publication has 13 references indexed in Scilit:
- Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigenThe Prostate, 1996
- Loss of HLA class I expression in prostate cancer: Implications for immunotherapyUrology, 1995
- Tuberculosis and cancer: parallels in host responses and therapeutic approaches?The Lancet, 1995
- Immunotherapy for TuberculosisClinical Immunotherapeutics, 1994
- Demonstration of a Rational Strategy for Human Prostate Cancer Gene TherapyJournal of Urology, 1994
- Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinomaEuropean Journal Of Cancer, 1994
- Impaired cytokine production in whole blood cell cultures of patients with urological carcinomasZeitschrift für Krebsforschung und Klinische Onkologie, 1993
- Unusual expression and localization of heat‐shock proteins in human tumor cellsInternational Journal of Cancer, 1992
- Leuprolide With and Without Flutamide in Advanced Prostate CancerCancer, 1990
- Bacillus Calmette-Guerin (BCG) adjuvant therapy in stage D prostate cancerUrology, 1982